This change aims to enhance the operating environment for pharmaceutical companies in the UK, supporting innovation and the sector’s growth.

Dr. Samantha Roberts, CEO of NICE, highlighted the government’s role in health spending and the introduction of new thresholds to benefit the life sciences.

NICE intends to raise the standard cost-effectiveness threshold (from £20,000 – £30,000) to £25,000 – £35,000 per QALY, potentially allowing an additional 3-5 medicines to be recommended annually.

Evaluations will include quality-adjusted life years (QALYs) and real-world evidence, with new health-related quality of life values derived from public input.

Changes will apply to new technology appraisals, and paused evaluations will be revisited under the new thresholds.

Companies are urged to submit evidence promptly and set fair prices.

Has the MFN framework given the government a nudge to confirm this change?

www.nice.org.uk/news/articles/changes-to-nice-s-cost-effectiveness-thresholds-confirmed